Agents intervening against delirium in the intensive care unit trial—Protocol for a secondary Bayesian analysis

Andersen‐Ranberg, Nina, Poulsen, Lone M., Perner, Anders, Hästbacka, Johanna, Morgan, Matthew P. G., Citerio, Giuseppe, Oxenbøll‐Collet, Marie, Weber, Sven‐Olaf, Andreasen, Anne Sofie, Bestle, Morten H., Uslu, Bülent, Pedersen, Helle B. S., Nielsen, Louise G., Damgaard, Kjeld, Jensen, Troels B., Sommer, Trine, Dey, Nilanjan, Mathiesen, Ole and Granholm, Anders 2022. Agents intervening against delirium in the intensive care unit trial—Protocol for a secondary Bayesian analysis. Acta Anaesthesiologica Scandinavica 10.1111/aas.14091

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (580kB)

Abstract

Background: Delirium is highly prevalent in the intensive care unit (ICU) and is associated with high morbidity and mortality. The antipsychotic haloperidol is the most frequently used agent to treat delirium although this is not supported by solid evidence. The agents intervening against delirium in the intensive care unit (AID‐ICU) trial investigates the effects of haloperidol versus placebo for the treatment of delirium in adult ICU patients. Methods: This protocol describes the secondary, pre‐planned Bayesian analyses of the primary and secondary outcomes up to day 90 of the AID‐ICU trial. We will use Bayesian linear regression models for all count outcomes and Bayesian logistic regression models for all dichotomous outcomes. We will adjust for stratification variables (site and delirium subtype) and use weakly informative priors supplemented with sensitivity analyses using sceptical priors. We will present results as absolute differences (mean differences and risk differences) and relative differences (ratios of means and relative risks). Posteriors will be summarised using median values as point estimates and percentile‐based 95% credibility intervals. Probabilities of any benefit/harm, clinically important benefit/harm and clinically unimportant differences will be presented for all outcomes. Discussion: The results of this secondary, pre‐planned Bayesian analysis will complement the primary frequentist analysis of the AID‐ICU trial and facilitate a nuanced and probabilistic interpretation of the trial results.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher:	Wiley
ISSN:	0001-5172
Date of First Compliant Deposit:	1 June 2022
Date of Acceptance:	9 May 2022
Last Modified:	15 May 2023 15:33
URI:	https://orca.cardiff.ac.uk/id/eprint/150195

Actions (repository staff only)

Edit Item